Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Combined with IFA and IFN-alpha for Patients with Urothelial Cancer (Phase I clinical study)

Phase 1

• Conditions: Advanced or recurrent urothelial cancer

• Registration Number: JPRN-UMIN000005859
• Lead Sponsor: Department of Urology, Sapporo Medical University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-28
• Study Completion: 2014-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria included (1) prior cancer therapy such as chemotherapy, radiation therapy, steroid therapy, or other immunotherapy within the previous 4 weeks, (2) the presence of other cancers that might influence the prognosis, (3) immunodeficiency or a history of splenectomy, (4) severe cardiac insufficiency, acute infection, or hematopoietic failure and (5) unsuitability for the trial based on clinical judgment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified